The Emirates Drug Establishment (EDE) has approved Wegovy (semaglutide), an oral once-daily treatment indicated for long-term weight management in adults living with obesity or overweight associated with weight-related medical conditions.
Bahrain's National Health Regulatory Authority (NHRA) has approved Wegovy (semaglutide) pills, an oral GLP-1 treatment for obesity, in the kingdom. With this, Bahrain has become the second GCC country, after the UAE, and the fifth country worldwide to make the medicine available to its citizens.
